Showing 4861-4870 of 5771 results for "".
- Ideaya Biosciences and Boston Children’s Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndromehttps://modernod.com/news/ideaya-biosciences-and-boston-childrens-hospital-collaborate-on-preclinical-evaluation-of-ide196-for-sturge-weber-syndrome/2477220/Ideaya Biosciences announced that the company has entered into a Sponsored Research Agreement with Boston Children’s Hospital for preclinical evaluation of the role of protein kinase C (PKC) in Sturge Weber syndrome (SWS), a rare neurocutaneous disorder characterized by capillary malformati
- Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry AMDhttps://modernod.com/news/gemini-therapeutics-enrolls-first-patient-in-phase-1-study-of-gem103-for-dry-amd/2477214/Gemini Therapeutics announced it has initiated enrollment in its phase 1 study of GEM103, a recombinant, native Complement Factor H (CFH) for the treatment of dry age-related macular degeneration. AMD is the leading cause of irreversible blindness in the western world—affecting millions of
- New Chair, Members Named to Eversight Board of Directorshttps://modernod.com/news/new-chair-members-named-to-eversight-board-of-directors/2477217/Eversight announced that two new members and a new chair have been named to its Board of Directors, effective Jan. 1, 2020. Joining the Eversight Board of Directors are Carolyn Welsh, Vice President & Chief Clinical Officer, NJ Sharing Network; and Mahmoud N. Ghazzi, MD, PhD, MPH, an e
- Tarsus Pharmaceuticals Raises $60 Million for Demodex Blepharitis Drug Trialhttps://modernod.com/news/tarsus-pharmaceuticals-raises-60-million-for-demodex-blepharitis-drug-trial/2477213/Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing. Tarsus will use the funds to initiate a phase 2b/3 trial in the United States of their lead product TP-03 for Demodex blepharitis and fuel phase 1 and 2 development of other clinical programs. An estimate
- Aerpio Pharmaceutical’s AKB-9778 Produced IOP Lowering with Minimal Hyperemia When Combined with Prostaglandinhttps://modernod.com/news/aerpio-pharmaceuticals-akb-9778-produced-iop-lowering-with-minimal-hyperemia-when-combined-with-prostaglandin/2477211/Aerpio Pharmaceuticals announced new results from the fifth cohort of subjects from a phase 1b trial of a topical ocular formulation of AKB-9778 providing evidence of tolerability and IOP reduction from patients in that cohort with ocular hypertension (OHT) or primary open angle glaucoma (POAG).<
- Aura Biosciences Appoints George Golumbeski, PhD, as Chairman of the Board of Directorshttps://modernod.com/news/aura-biosciences-appoints-george-golumbeski-phd-as-chairman-of-the-board-of-directors/2477212/Aura Biosciences announced the appointment of George Golumbeski, PhD, as Chairman of its Board of Directors. Dr. Golumbeski is a biopharmaceutical business leader with over 25 years of experience in the biotechnology industry. “George’s extensive experience will be invaluable to Aura as we
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- The Firmament Group Invests in Three Ophthalmology Practices and an ASC in St. Louishttps://modernod.com/news/the-firmament-group-invests-in-three-ophthalmology-practices-and-an-asc-in-st-louis/2477206/The Firmament Group announced an investment in three ophthalmology practices and an ambulatory surgery center in St. Louis. Terms of the deal were not disclosed. Firmament previously invested in practices in Southern Florida
- Bausch + Lomb Launches Expanded Parameters for Biotrue ONEday for Astigmatism Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-launches-expanded-parameters-for-biotrue-oneday-for-astigmatism-daily-disposable-contact-lenses/2477205/Bausch + Lomb announced the US launch of expanded parameters for Biotrue ONEday for Astigmatism daily disposable contact lenses. The expansion will increase the toric parameter range by more than 60%, offering eye care professionals and their astigmatic patients the largest parameter offering of
- ProtoKinetix AAGP Dry Eye Therapy Testing Resultshttps://modernod.com/news/protokinetix-aagp-dry-eye-therapy-testing-results/2477203/ProtoKinetix announced that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP and to date have shown no sign of irritation. Based on this, ProtoKinetix is shipping AAGP to EyeCRO to commence testing dry eye disease efficacy. This testin